JP2018528410A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528410A5 JP2018528410A5 JP2018503182A JP2018503182A JP2018528410A5 JP 2018528410 A5 JP2018528410 A5 JP 2018528410A5 JP 2018503182 A JP2018503182 A JP 2018503182A JP 2018503182 A JP2018503182 A JP 2018503182A JP 2018528410 A5 JP2018528410 A5 JP 2018528410A5
- Authority
- JP
- Japan
- Prior art keywords
- sample
- cells
- polypeptide
- detecting
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562196409P | 2015-07-24 | 2015-07-24 | |
| US62/196,409 | 2015-07-24 | ||
| PCT/EP2016/065653 WO2017016805A1 (en) | 2015-07-24 | 2016-07-04 | Methods for detecting tissue infiltrating nk cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018528410A JP2018528410A (ja) | 2018-09-27 |
| JP2018528410A5 true JP2018528410A5 (https=) | 2019-07-11 |
| JP6944925B2 JP6944925B2 (ja) | 2021-10-06 |
Family
ID=56368945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018503182A Active JP6944925B2 (ja) | 2015-07-24 | 2016-07-04 | 組織浸潤ｎｋ細胞を検出する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10736963B2 (https=) |
| EP (1) | EP3325967B1 (https=) |
| JP (1) | JP6944925B2 (https=) |
| KR (1) | KR102554507B1 (https=) |
| CN (1) | CN107850596B (https=) |
| AU (1) | AU2016299166B2 (https=) |
| CA (1) | CA2990520C (https=) |
| WO (1) | WO2017016805A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6822849B2 (ja) * | 2014-06-27 | 2021-01-27 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 多重特異的ＮＫｐ４６結合タンパク質 |
| IL250579B2 (en) | 2014-10-10 | 2023-05-01 | Innate Pharma | blocking cd73 |
| AU2016299166B2 (en) | 2015-07-24 | 2022-03-31 | Innate Pharma | Methods for detecting tissue infiltrating NK cells |
| SG11202111106WA (en) | 2019-04-23 | 2021-11-29 | Innate Pharma | Cd73 blocking antibodies |
| CN110187107A (zh) * | 2019-04-26 | 2019-08-30 | 温州医科大学 | 一种基于肿瘤组织浸润免疫细胞特征建立的结直肠癌预后评估装置及方法 |
| CN110862963B (zh) * | 2019-11-27 | 2021-08-27 | 沣潮医药科技（上海）有限公司 | 蜕膜nk细胞及其细胞亚群在制备不孕不育相关疾病治疗药物中的用途 |
| US20230348854A1 (en) * | 2020-05-08 | 2023-11-02 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Chimeric antigen receptors (cars) targeting natural killer cells |
| CN116125078A (zh) * | 2023-01-17 | 2023-05-16 | 复旦大学附属中山医院 | 一种检测ctc抵抗nk细胞杀伤的试剂盒及其应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE423848T1 (de) * | 1999-11-15 | 2009-03-15 | Innate Pharma | Auslösender rezeptor der an der natürlichen cytotoxizität der menschlichen natürlichen killerzellen (natural killer cells) beteiligt ist und antikörper die diesen rezeptor identifizieren |
| US6979546B2 (en) | 1999-11-15 | 2005-12-27 | Universita Di Genova | Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same |
| EP1219637A1 (en) | 2000-12-27 | 2002-07-03 | Innate Pharma | Polypeptides having a triggering NK activity and biological applications |
| CA2454185A1 (en) | 2001-07-19 | 2003-01-30 | Innate Pharma | Ntb-a, a surface molecule involved in natural killer cells activity |
| WO2004056392A1 (en) | 2002-12-23 | 2004-07-08 | Innate Pharma | Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same |
| US7803376B2 (en) | 2003-07-24 | 2010-09-28 | Innate Pharma S.A. | Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds |
| WO2005105848A1 (en) | 2004-04-30 | 2005-11-10 | Innate Pharma | Compositions and methods for enhancing nk cell activity |
| WO2005105849A1 (en) | 2004-04-30 | 2005-11-10 | Innate Pharma | Compositions and methods for treating proliferative disorders such as nk-type ldgl |
| EP2287195B1 (en) | 2004-07-01 | 2019-05-15 | Novo Nordisk A/S | Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy |
| ATE548389T1 (de) | 2004-08-03 | 2012-03-15 | Innate Pharma | Therapeutische und diagnostische verfahren und zusammensetzungen zum targeting von 4ig-b7-h3 und dem entsprechenden nk-zellen-rezeptor |
| AU2005321017B2 (en) | 2004-12-28 | 2011-02-24 | Innate Pharma S.A. | Monoclonal antibodies against NKG2A |
| CN101103043A (zh) | 2005-01-06 | 2008-01-09 | 诺和诺德公司 | Kir结合剂和使用其的方法 |
| EP3072522B1 (en) | 2005-01-06 | 2019-04-24 | Novo Nordisk A/S | Anti-kir combination treatments and methods |
| US20080196111A1 (en) | 2005-03-18 | 2008-08-14 | Innate Pharma S.A. | Expression Vectors and Methods for Obtaining Nk Cell Specific Expression |
| AU2006301163B2 (en) | 2005-10-14 | 2012-02-23 | Innate Pharma | Compositions and methods for treating proliferative disorders |
| WO2007103901A2 (en) * | 2006-03-06 | 2007-09-13 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Autologous natural killer cells and lymphodepleting chemotherapy for the treatment of cancer |
| CN106963947A (zh) | 2010-11-22 | 2017-07-21 | 伊纳特医药股份有限公司 | Nk细胞调节治疗和用于治疗血液恶性疾病的方法 |
| SG10201603962TA (en) | 2011-05-25 | 2016-07-28 | Innate Pharma Sa | Anti-kir antibodies for the treatment of inflammatory disorders |
| US20140234342A1 (en) | 2011-06-21 | 2014-08-21 | Innate Pharma | Nkp46-mediated nk cell tuning |
| EP2812027A1 (en) | 2012-02-07 | 2014-12-17 | Innate Pharma | Mica binding agents |
| EP2841563B1 (en) | 2012-04-24 | 2019-06-12 | Dan S. Kaufman | Method for developing natural killer cells from stem cells |
| EP2687852A1 (en) * | 2012-07-17 | 2014-01-22 | Laboratorios Del. Dr. Esteve, S.A. | Method for diagnosing and treating chronic fatigue syndrome |
| US9789182B2 (en) | 2012-10-23 | 2017-10-17 | Bristol-Myers Squibb Company | Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer |
| DK2956482T3 (en) | 2013-02-14 | 2017-10-16 | Innate Pharma | TREATMENT OF PERFECT T cell lymphoma |
| DK2958941T3 (da) | 2013-02-20 | 2019-06-24 | Innate Pharma | Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom |
| JP6822849B2 (ja) | 2014-06-27 | 2021-01-27 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 多重特異的ＮＫｐ４６結合タンパク質 |
| CA2952532A1 (en) | 2014-06-27 | 2015-12-30 | Innate Pharma | Multispecific antigen binding proteins |
| JP2017532025A (ja) | 2014-09-10 | 2017-11-02 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 交差反応性ｓｉｇｌｅｃ抗体 |
| CA2959463A1 (en) | 2014-09-16 | 2016-03-24 | Innate Pharma | Treatment regimens using anti-nkg2a antibodies |
| SMT202000562T1 (it) | 2014-09-16 | 2020-11-10 | Innate Pharma | Neutralizzazionne delle vie inibitorie nei linfociti |
| EP3209687A1 (en) | 2014-10-23 | 2017-08-30 | Innate Pharma | Treatment of cancers using anti-nkg2a agents |
| US9767555B2 (en) | 2015-01-05 | 2017-09-19 | Case Western Reserve University | Disease characterization from fused pathology and radiology data |
| WO2016207278A1 (en) | 2015-06-23 | 2016-12-29 | Innate Pharma | Multispecific nk engager proteins |
| DK3313876T3 (da) | 2015-06-23 | 2025-04-22 | Innate Pharma | Multispecifikke antigenbindende proteiner |
| AU2016299166B2 (en) | 2015-07-24 | 2022-03-31 | Innate Pharma | Methods for detecting tissue infiltrating NK cells |
| CA3004972A1 (en) | 2015-11-17 | 2017-05-26 | Innate Pharma | Siglec-10 antibodies |
| CN115925933A (zh) | 2015-12-28 | 2023-04-07 | 依奈特制药公司 | NKp46结合蛋白的可变区 |
| CA3012055A1 (en) | 2016-01-21 | 2017-07-27 | Innate Pharma | Neutralization of inhibitory pathways in lymphocytes |
| WO2017153433A1 (en) | 2016-03-08 | 2017-09-14 | Innate Pharma | Siglec neutralizing antibodies |
| RU2018128215A (ru) | 2016-03-15 | 2020-04-15 | Иннейт Фарма | Антитела против mica |
| WO2018115262A1 (en) | 2016-12-23 | 2018-06-28 | Innate Pharma | Heterodimeric antigen binding proteins |
| WO2018138032A2 (en) | 2017-01-24 | 2018-08-02 | Innate Pharma | NKp46 BINDING AGENTS |
-
2016
- 2016-07-04 AU AU2016299166A patent/AU2016299166B2/en active Active
- 2016-07-04 CA CA2990520A patent/CA2990520C/en active Active
- 2016-07-04 EP EP16736054.4A patent/EP3325967B1/en active Active
- 2016-07-04 US US15/747,190 patent/US10736963B2/en active Active
- 2016-07-04 CN CN201680040445.XA patent/CN107850596B/zh active Active
- 2016-07-04 WO PCT/EP2016/065653 patent/WO2017016805A1/en not_active Ceased
- 2016-07-04 JP JP2018503182A patent/JP6944925B2/ja active Active
- 2016-07-04 KR KR1020187004883A patent/KR102554507B1/ko active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018528410A5 (https=) | ||
| Kidman et al. | Characteristics of TCR repertoire associated with successful immune checkpoint therapy responses | |
| Dora et al. | Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution | |
| Bonaventura et al. | Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy | |
| Parkhurst et al. | T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis | |
| JP2021054859A5 (https=) | ||
| ES2922525T3 (es) | Marcadores desregulados selectivamente en células T reguladoras que infiltran tumores | |
| Granier et al. | Tim-3 expression on tumor-infiltrating PD-1+ CD8+ T cells correlates with poor clinical outcome in renal cell carcinoma | |
| Morita et al. | Olfactory receptor family 7 subfamily C member 1 is a novel marker of colon cancer–initiating cells and is a potent target of immunotherapy | |
| Wan et al. | Surface-immobilized aptamers for cancer cell isolation and microscopic cytology | |
| Ascierto et al. | Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients | |
| ES2355388T3 (es) | Métodos para la detección precoz de cáncer. | |
| JP2016533395A5 (https=) | ||
| HRP20220131T1 (hr) | Nova terapija s t-staničnim receptorima i imunološka terapija koja koristi iste | |
| Feldman et al. | PAX5-positive T-cell anaplastic large cell lymphomas associated with extra copies of the PAX5 gene locus | |
| Zhang et al. | TCR repertoire intratumor heterogeneity of CD4+ and CD8+ T cells in centers and margins of localized lung adenocarcinomas | |
| Shen et al. | PD-1 does not mark tumor-infiltrating CD8+ T cell dysfunction in human gastric cancer | |
| Janikova et al. | Identification of CD133+/nestin+ putative cancer stem cells in non-small cell lung cancer | |
| Windrichova et al. | MIC1/GDF15 as a bone metastatic disease biomarker | |
| RU2016144178A (ru) | Антитело против muc1 или его антигенсвязывающий фрагмент и его применение | |
| Jiao et al. | Intratumor expanded T cell clones can be non-sentinel lymph node derived in breast cancer revealed by single-cell immune profiling | |
| Xu et al. | γδ T cells recognize tumor cells via CDR3δ region | |
| JP2020516668A5 (https=) | ||
| JP2016536568A5 (https=) | ||
| Arianfar et al. | Suppression of CD56bright NK cells in breast cancer patients is associated with the PD-1 and TGF-βRII expression |